Patents by Inventor Bírgítte Andersen

Bírgítte Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of inflammatory bowel diseases with mammal beta defensins
    Patent number: 8802621
    Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: August 12, 2014
    Assignee: Defensin Therapeutics ApS
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • Oral Treatment of Inflammatory Bowel Disease
    Publication number: 20140213521
    Abstract: The present invention relates to treatment of an inflammatory bowel disease by simultaneous or successive parental and oral administration of a mammalian beta defensin.
    Type: Application
    Filed: July 5, 2012
    Publication date: July 31, 2014
    Applicant: NOVOZYMES A/S
    Inventors: Tanja Maria Rosenkilde Kjær, Birgitte Andersen, Karoline Sidelmann Brinch
  • Treatment of Inflammatory Bowel Diseases with Mammal Beta Defensins
    Publication number: 20140135258
    Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
    Type: Application
    Filed: January 30, 2014
    Publication date: May 15, 2014
    Applicant: Defensin Therapeutics ApS
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • FGF21 ANALOGUES AND DERIVATIVES
    Publication number: 20130252884
    Abstract: Novel analogues of Fibroblast Growth Factor 21 (FGF21), derivatives thereof having a modifying moiety covalently attached thereto, and pharmaceutical use of these analogues and derivatives, in particular, for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD) are described.
    Type: Application
    Filed: June 6, 2011
    Publication date: September 26, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Patrick William Garibay, Helle Woeldike, Xujia Zhang, Henning Thoegersen, Peter Kresten Nielsen, Birgitte Andersen, Jishu Wang, Kristian Sass Bak-Jensen, Tina Moeller Tagmose
  • N-TERMINAL MODIFIED FGF21 COMPOUNDS
    Publication number: 20130190232
    Abstract: Analogues of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD).
    Type: Application
    Filed: July 18, 2011
    Publication date: July 25, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Tina Moeller Tagmose, Patrick William Garibay, Xujia Zhang, Henning Thoegersen, Peter Kresten Nielsen, Birgitte Andersen, Jishu Wang, Kristian Sass Bak-Jensen, Helle Fabricius Woeldike
  • ORAL TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Publication number: 20130172235
    Abstract: The present invention relates to treatment of an inflammatory bowel disease by simultaneous or successive parental and oral administration of a mammalian beta defensin.
    Type: Application
    Filed: July 6, 2012
    Publication date: July 4, 2013
    Applicant: Novozymes A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Birgitte Andersen, Karoline Sidelmann Brinch
  • NOVEL IMMUNOMODULATORY PEPTIDE
    Publication number: 20130052213
    Abstract: The present invention relates a cleaved mammalian beta defensin with immunomodulatory properties. The cleaved or truncated peptides may be as potent as the full length mammalian beta defensins and may be used in the treatment of immunological and autoimmune disorders including but not limited to inflammatory bowel disease, and rheumatoid arthritis.
    Type: Application
    Filed: August 17, 2012
    Publication date: February 28, 2013
    Applicant: Novozymes A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Birgitte Andersen
  • Treatment of Rheumatoid Arthritis With Mammal Beta Defensins
    Publication number: 20120309686
    Abstract: The present invention relates to treatment of rheumatoid arthritis with mammal beta defensins.
    Type: Application
    Filed: July 9, 2012
    Publication date: December 6, 2012
    Applicant: Novozymes Adenium Biotech A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • Treatment of Inflammatory Bowel Diseases With Mammal Beta Defensins
    Publication number: 20120309678
    Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
    Type: Application
    Filed: July 9, 2012
    Publication date: December 6, 2012
    Applicant: Novozymes Adenium Biotech A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • Treatment of rheumatoid arthritis with mammal beta defensins
    Patent number: 8232248
    Abstract: The present invention relates to treatment of rheumatoid arthritis with mammal beta defensins.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: July 31, 2012
    Assignee: Novozymes Adenium Biotech A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • Treatment of inflammatory bowel diseases with mammal beta defensins
    Patent number: 8232242
    Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: July 31, 2012
    Assignee: Novozymes Adenium Biotech A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • GLP-1 AND FGF21 COMBINATIONS FOR TREATMENT OF DIABETES TYPE 2
    Publication number: 20120172298
    Abstract: The invention relates to the use of a Fibroblast Growth Factor 21 (FGF21) compound and a Glucagon-Like Peptide 1 (GLP-1) compound in combination for the preparation of a medicament for the treatment of diabetes, more in particular type 2 diabetes, as well as pharmaceutical compositions comprising certain FGF21 and GLP-1 compounds in combination, together with a pharmaceutically acceptable carrier. The combination has a significant effect on parameters of relevance for diabetes type 2, viz. on the viability of beta cells ex vivo in the presence of free fatty acids, on caspase activity of beta cells ex vivo (a measure of cell apoptosis), and a blood glucose lowering effect on db/db mice in vivo.
    Type: Application
    Filed: June 8, 2010
    Publication date: July 5, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Birgitte Andersen, Ann Maria Kruse Hansen, Bidda Charlotte Rolin
  • FGF21 ANALOGUES AND DERIVATIVES
    Publication number: 20120035099
    Abstract: Derivatives of Fibroblast Growth Factor 21 which have improved properties for treating diabetes can be prepared by a recombinant process.
    Type: Application
    Filed: June 6, 2011
    Publication date: February 9, 2012
    Applicant: NOVO NORDISK A/S
    Inventors: WILLIAM PATRICK GARIBAY, HELLE WÖLDIKE, XUJIA ZHANG, HENNING THØGERSEN, PETER KRESTEN NIELSEN, BIRGITTE ANDERSEN, JISHU WANG, KRISTIAN SASS BAK-JENSEN, TINA MØLLER TAGMOSE
  • TREATMENT OF INFLAMMATORY BOWEL DISEASES WITH MAMMAL BETA DEFENSINS
    Publication number: 20110251139
    Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
    Type: Application
    Filed: June 13, 2011
    Publication date: October 13, 2011
    Applicant: NOVOZYMES A/S
    Inventors: TANJA MARIA ROSENKILDE KJAER, THOMAS KRUSE, PER HOLSE MYGIND, KAROLINE SIDELMANN BRINCH, SOEREN KJAERULFF, BIRGITTE ANDERSEN
  • FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use
    Publication number: 20100216715
    Abstract: The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability.
    Type: Application
    Filed: January 22, 2010
    Publication date: August 26, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Tina Møller Tagmose, Patrick William Garibay, Bírgítte Andersen, Jishu Wang, Kílían Waldemar Conde-Frieboes, Kristían Sass Bak-Jensen, Henning Thøgersen, Helle Wöldike, Peter Kresten Nielsen, Rita Slaaby, Xujia Zhang, Birgit Wieczorek
  • Treatment Of Inflammatory Bowel Diseases With Mammal Beta Defensins
    Publication number: 20100016230
    Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
    Type: Application
    Filed: July 17, 2009
    Publication date: January 21, 2010
    Applicant: Novozymes A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • Treatment Of Rheumatoid Arthritis With Mammal Beta Defensins
    Publication number: 20100016231
    Abstract: The present invention relates to treatment of rheumatoid arthritis with mammal beta defensins.
    Type: Application
    Filed: July 17, 2009
    Publication date: January 21, 2010
    Applicant: Novozymes A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • Treatment Of Inflammatory Diseases With Mammal Beta Defensins
    Publication number: 20100016232
    Abstract: The present invention relates to suppression of TNF-alpha activity with mammal beta defensins, which has utility in the treatment of pathological conditions associated with tumor necrosis factor alpha.
    Type: Application
    Filed: July 17, 2009
    Publication date: January 21, 2010
    Applicant: Novozymes A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen